RPCEC00000080
Completed
Phase 4
Impact of Recombinant Human Erythropoietin(ior EPO-CIM)in oncology pediatric patients with post chemo and /or radiotherapy.
Center of Molecular Immunology(CIM)0 sites161 target enrollmentJuly 3, 2009
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Anemia secondary to chemo and/or radiotherapy.
- Sponsor
- Center of Molecular Immunology(CIM)
- Enrollment
- 161
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Patients that fulfill with diagnostic criteria. 2\.Patients with cytological and/or histological diagnosis of cancer of any localization that are receiving chemotherapy and/or radiotherapy. 3\.Patients whose parents or tutors granted written consent for participation in the study. 4\.Patients aged between 1 and 18 years.
Exclusion Criteria
- •1\.Patients with known hypersensitivity to products derived from mammalian cells or hypersensitivity to human albumin. 2\.Patients pregnant or breastfeeding. 3\.Patients with active hemorrhage or hemolysis. 4\.Patients with non\-controlled arterial hypertension.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
Impact of Human Recombinant Erithoropoietin (ior EPOCIM) in cancer patients with post Chemo and Radiotherapy induced anemia.Anemia secondary to chemo and/or radiotherapy.RPCEC00000079Center of Molecular Immunology(CIM)338
Completed
Phase 1
The benefits of Erythropoietin in reducing the need for blood transfusions in patients receiving chemotherapysolid insitu tumor of the body.In situ neoplasmsD00-D09IRCT2015061822805N1Vice Chancellor for research of Tabriz University of Medical Sciences60
Not yet recruiting
Not Applicable
Effect of recombinant human erythropoietin administration before cardiopulmonary bypass on the development of postoperative acute kidney injury in patients undergoing valvular heart surgeryDiseases of the circulatory systemKCT0000696Asan Medical Center228
Not yet recruiting
Phase 3
Erythropoietin for Perinatal asphyxiaHealth Condition 1: null- Admitted to NICU for perinatal asphyxiaCTRI/2018/04/013331Dr Atul Londhe
Completed
Not Applicable
Recombinant human erythropoietin therapy in critically ill patients: a dose response studyCritically ill patients with anaemiaHaematological DisordersAnaemiaISRCTN48523317Janssen-Cilag (Greece)148